• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance

    3/26/24 7:01:00 AM ET
    $BLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BLUE alert in real time by email

    - Cash runway through Q1 2026 following announcement of a $175 million term loan facility with Hercules Capital -

    - 9 patient starts to date in 2024 (7 ZYNTEGLO, 2 SKYSONA); 85 to 105 patient starts anticipated across the portfolio in 2024 -

    - First government outcomes-based agreement for sickle cell disease signed with Michigan Medicaid -

    - 62 qualified treatment centers (QTCs) activated -

    - Full year 2023 revenue of $29.5 million with $7.8 million generated in the fourth quarter -

    - Management to host conference call today, March 26, 2024 at 8:00 am ET -

    bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird bio" or the "Company") today reported fourth quarter and annual financial results and business highlights for the year ended December 31, 2023, including recent commercial and operational progress.

    "In 2023, bluebird established a validated, commercial gene therapy strategy that brought ZYNTEGLO and SKYSONA to individuals living with beta-thalassemia and cerebral adrenoleukodystrophy. Building on that foundation, today we are positioned for robust commercial uptake of LYFGENIA for sickle cell disease, with a substantial QTC network in place, favorable Medicaid coverage being established, and demonstrated strong patient demand," said Andrew Obenshain, chief executive officer, bluebird bio. "Our recent agreement with Hercules Capital meaningfully extends our cash runway, and further enables us to capitalize on our commercial head start and bring our transformative gene therapies to patients and their families. In 2024, we anticipate between 85 to 105 patient starts across our three FDA approved therapies, laying the foundation for strong revenue growth."

    RECENT COMPANY HIGHLIGHTS

    Up to $175 million Debt Financing with Hercules Capital

    • On March 18, 2024, bluebird announced that it had entered into a five-year term loan facility with Hercules Capital. Under the terms of the agreement, the Company may draw up to $175 million, available in four tranches. The first tranche of $75 million was drawn at closing. The Company may draw upon two additional tranches of $25 million each, subject to satisfaction of certain conditions, including achievement of commercial milestones. The facility also provides for a fourth tranche of $50 million, available at the lender's discretion.
    • Based on launch estimates and current business plans, and assuming three tranches totaling $125 million are executed, the transaction is projected to extend the Company's cash runway through Q1 2026.

    COMMERCIAL LAUNCH UPDATES

    Strong patient uptake across portfolio

    • First LYFGENIA patient start imminent; multiple patients enrolled and preparing for treatment across QTC network.
    • Continued strong, linear growth for ZYNTEGLO with 7 patient starts since the beginning of 2024, in addition to 20 patient starts completed for ZYNTEGLO in 2023.
    • Completed 2 patient starts for SKYSONA since the beginning of 2024, in addition to 6 patient starts completed for SKYSONA in 2023.

    Validated access and reimbursement strategy is driving favorable coverage landscape

    • In the first quarter of 2024, bluebird signed its first Medicaid outcomes-based agreement for LYFGENIA with the state of Michigan.
    • In addition to the Medicaid outcomes-based agreement, bluebird has signed four outcomes-based agreements for LYFGENIA with national commercial payer organizations and published coverage policies cover more than 200 million U.S. lives.
    • Discussions are ongoing with more than 15 Medicaid agencies representing 80% of Medicaid-insured individuals with sickle cell disease in the U.S. and the Company is engaged with the Center for Medicare and Medicaid Innovation (CMMI) on its Cell and Gene Therapy Access Model demonstration.
    • Timely access to ZYNTEGLO and SKYSONA has continued, with zero ultimate denials for either therapy across both Medicaid and commercial payers.

    Substantial QTC footprint established

    • bluebird has activated 62 QTCs for ZYNTEGLO (defined as a signed MSA); capitalizing on launch synergies, 49 centers are already receiving referrals for LYFGENIA.
    • Five centers are also activated to administer SKYSONA for patients with cerebral adrenoleukodystrophy (CALD).
    • The Company anticipates continued QTC network expansion across its portfolio in 2024.

    LOVO-CEL CLINICAL TRIAL UPDATE

    • Enrollment is ongoing for the HGB-210 study evaluating lovo-cel for patients under the age of 12. The Company anticipates enrollment to be complete in Q4 2024.

    2024 GUIDANCE

    • The Company anticipates 85 to 105 patient starts (cell collections) combined across all three of its FDA approved therapies (LYFGENIA, ZYNTEGLO, SKYSONA) in 2024. Consistent with previous quarters, bluebird plans to provide quarterly updates on patient starts for each of its therapies.
    • Gross-to-net discounts across all three products are expected to be in the range of 20% to 25% of gross revenue in 2024 and will fluctuate based on product and payer mix, and well as utilization of outcomes-based agreements for LYFGENIA and ZYNTEGLO.
    • Based on projected timelines from cell collection to infusion, the Company expects to recognize revenue from its first infusion of LYFGENIA in the third quarter of 2024.

    FOURTH QUARTER AND ANNUAL FINANCIAL HIGHLIGHTS

    • Cash Position: The Company's cash, cash equivalents and restricted cash balance was approximately $275 million, including restricted cash of approximately $53 million, as of December 31, 2023.



      Based on launch trajectory and current business plans, bluebird expects its cash and cash equivalents excluding restricted cash and assuming three tranches totaling $125 million in proceeds from its term loan facility are executed, will be sufficient to meet bluebird's planned operating expenses and capital expenditure requirements through Q1 2026.



      In the fourth quarter of 2023, the Company entered into a factoring agreement which is accelerating cash collection related to patient starts across its portfolio of approved therapies.
    • Revenue, net: Total revenue, net was $7.8 million for the three months ended December 31, 2023, compared to $0.1 million for the three months ended December 31, 2022.



      Total revenue, net was $29.5 million for the twelve months ended December 31, 2023, compared to $3.6 million for the twelve months ended December 31, 2022. The increase of $25.9 million was primarily due to SKYSONA and ZYNTEGLO product revenue.



      For the year ended December 31, 2023, product revenues by therapy represent $16.7 million attributable to ZYNTEGLO and $12.4 million attributable to SKYSONA, with gross-to-net discounts of approximately 19% across both products.

    On March 26, 2024, bluebird announced that it will restate its consolidated financial statements for 2022, and for the first three quarters of both 2022 and 2023 in its Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Form 10-K"). The restatements relate to the identification of embedded leases and the treatment of non-lease components contained in lease agreements with contract manufacturers. As a result, the Company anticipates recording an increase in lease assets and lease liabilities, as well as an increase in non-cash interest expense in each restated period. The Company does not expect the restatement to result in any impact on its cash position or revenue. bluebird anticipates filing its 2023 Form 10-K, inclusive of the restatement no later than April 16, 2024.

    The financial results included in this press release represent the most current information available to the Company's management. The Company expects that its actual results to be reported in its 2023 Form 10-K will not differ materially from the results included herein, however, these results are subject to change following the completion of the Company's financial close procedures and the audit of its consolidated financial statements for the year ended December 31, 2023.

    CONFERENCE CALL DETAILS

    bluebird will hold a conference call to discuss its fourth quarter and 2023 annual results and business updates today, Tuesday, March 26, 2024, at 8:00 am ET.

    To access the live conference call via telephone, please register at this link to receive a dial in number and unique PIN.

    The live webcast of the call may be accessed by visiting the "Events & Presentations" page within the Investors & Media section of the bluebird website at http://investor.bluebirdbio.com. A replay of the webcast will be available on the bluebird website for 90 days following the event.

    About bluebird bio, Inc.

    bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days.

    Founded in 2010, bluebird has been setting the standard for gene therapy for more than a decade—first as a scientific pioneer and now as a commercial leader. bluebird has an unrivaled track record in bringing the promise of gene therapy out of clinical studies and into the real-world setting, having secured FDA approvals for three therapies in under two years. Today, we are proving and scaling the commercial model for gene therapy and delivering innovative solutions for access to patients, providers, and payers.

    With a dedicated focus on severe genetic diseases, bluebird has the largest and deepest ex-vivo gene therapy data set in the field, with industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.

    bluebird continues to forge new paths as a standalone commercial gene therapy company, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds.

    bluebird bio, LYFGENIA, ZYNTEGLO and SKYSONA are registered trademarks of bluebird bio, Inc. All rights reserved.

    Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements, such as statements regarding the number of anticipated patient starts across bluebird's portfolio of therapies and the timing of the first LYFGENIA patient start, expectations regarding gross-to-net discounts, the Company's anticipated cash runway, the Company's expectations regarding its ability to access future tranches of its term loan facility, the Company's expectations with respect to the commercialization of LYFGENIA, including without limitation, the potential for robust commercial uptake of LYFGENIA, the timing of revenue recognition, patient demand for the therapy, bluebird's ability to establish favorable coverage for its therapies, including its ability successfully partner with payers and its expectations for expansion of its QTC network , expectations with respect to the completion of enrollment in HGB-210, and expectations regarding the Company's restatement of certain historical financial statements and the timing for filing of its 2023 10-K. Such forward-looking statements are based on historical performance and current expectations and projections about bluebird's future goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond bluebird's control and could cause bluebird's future goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect bluebird bio's business, particularly those identified in the risk factors discussion in bluebird bio's Annual Report on Form 10-K for the year ended December 31, 2022, as updated by its subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. These risks and uncertainties include, but are not limited to: delays and challenges in bluebird's commercialization and manufacturing of its products; the internal and external costs required for bluebird's ongoing and planned activities, and the resulting impact on expense and use of cash, has been, and may in the future be, higher than expected which has caused bluebird, and may in the future cause bluebird to use cash more quickly than it expects or change or curtail some of its plans or both; substantial doubt exists regarding bluebird's ability to continue as a going concern; bluebird's expectations as to expenses, cash usage and cash needs may prove not to be correct for other reasons such as changes in plans or actual events being different than bluebird's assumptions; the risk that the efficacy and safety results from bluebird's prior and ongoing clinical trials will not continue or be seen in the commercial context; the risk that bluebird is not able to activate QTCs on the timeframe that it expects; the risk that the QTCs experience delays in their ability to enroll or treat patients; the risk that bluebird experiences delays in establishing operational readiness across its supply chain following approval to support treatment in the commercial context; the risk that there is not sufficient patient demand or payer reimbursement to support continued commercialization of the Company's therapies; the risk of insertional oncogenic or other safety events associated with lentiviral vector, drug product, or myeloablation, including the risk of hematologic malignancy; and the risk that bluebird's products, including LYFGENIA, will not be successfully commercialized. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, bluebird bio undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240326211450/en/

    Get the next $BLUE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BLUE

    DatePrice TargetRatingAnalyst
    2/24/2025Underweight → Neutral
    Analyst
    2/24/2025$29.00Overweight
    Analyst
    11/18/2024Neutral → Underweight
    Analyst
    11/15/2024Neutral → Underweight
    JP Morgan
    11/15/2024$3.00 → $0.50Buy → Neutral
    BofA Securities
    8/15/2024Overweight → Neutral
    JP Morgan
    12/11/2023Hold → Reduce
    HSBC Securities
    12/8/2023$3.00 → $7.00Underweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $BLUE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital

      bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird") today reminds all stockholders, including individual stockholders, to promptly tender their shares into the tender offer by Carlyle and SK Capital to purchase all outstanding shares of bluebird common stock by 11:59 p.m. Eastern on May 12, 2025. Stockholders that hold shares of bluebird common stock through a broker or other nominee may be subject to a processing cutoff that is prior to the tender deadline, so it is important to act now. Every share tendered by stockholders is important and it is important to tender now. If a majority of the outstanding shares of bluebird common stock are not tendered, the tender offer will not be completed, a

      5/9/25 8:30:00 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio

      bluebird Board of Directors unanimously supports the transaction as the only viable option for stockholders to receive consideration for their shares and recommends that all stockholders immediately tender their shares into the offer Parties expect the merger to be completed promptly following the successful completion of the ongoing tender offer bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird" or "the Company"), Carlyle (NASDAQ:CG) ("Carlyle"), SK Capital Partners, LP ("SK Capital") and Beacon Parent Holdings, L.P. ("Parent") announced today that all required regulatory approvals to complete the previously announced acquisition of the Company by Carlyle and SK Capital have been received. No

      5/5/25 4:00:00 PM ET
      $BLUE
      $CG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Investment Managers
      Finance
    • bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement

      bluebird Board reaffirms unanimous recommendation in support of transaction with Carlyle and SK Capital and recommends all stockholders tender into the current agreement by May 2, 2025 bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird" or "the Company") today announced that after three weeks of engagement, including a timeline extension, Ayrmid Ltd. ("Ayrmid") has not submitted a binding proposal to acquire bluebird and has not obtained necessary financing. In consultation with its financial and legal advisors, the bluebird Board of Directors (the "Board") reaffirms its recommendation in support of the transaction with Carlyle and SK Capital and recommends all stockholders tender into the curren

      4/16/25 8:00:00 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BLUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Colvin Richard A sold $2,289 worth of shares (584 units at $3.92), decreasing direct ownership by 7% to 7,610 units (SEC Form 4)

      4 - bluebird bio, Inc. (0001293971) (Issuer)

      3/5/25 4:05:53 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Klima Thomas J sold $1,960 worth of shares (500 units at $3.92), decreasing direct ownership by 6% to 7,878 units (SEC Form 4)

      4 - bluebird bio, Inc. (0001293971) (Issuer)

      3/5/25 4:05:41 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Obenshain Andrew sold $3,610 worth of shares (921 units at $3.92), decreasing direct ownership by 5% to 18,327 units (SEC Form 4)

      4 - bluebird bio, Inc. (0001293971) (Issuer)

      3/5/25 4:05:24 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BLUE
    Leadership Updates

    Live Leadership Updates

    See more
    • 2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner

      CHICAGO, June 2, 2024 /PRNewswire/ -- 2Flo Ventures, an emerging venture capital firm and startup studio focused on the discovery, development, and commercialization of healthcare solutions that address disparities in outcomes and health equity broadly, is pleased to announce the addition of Dr. Charlotte Jones-Burton as a Partner and Head of Life Science Product Development and Strategy. 2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a PartnerDr. Jones-Burton brings to 2Flo Ventures nearly two decades of experience in th

      6/2/24 10:15:00 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • bluebird bio Appoints O. James Sterling as Chief Financial Officer

      bluebird bio, Inc. (NASDAQ:BLUE) today announced that O. James Sterling, has been appointed chief financial officer (CFO), effective June 10, 2024. Mr. Sterling most recently served as chief financial officer of Renalytix plc, a diagnostics company focused on clinical management of kidney disease. "We are thrilled to welcome James to bluebird bio. We are confident that his extensive experience in the healthcare sector and knowledge of the capital markets will position us well as we work to prove the commercial gene therapy model, and demonstrate progress on our path to profitability," said Andrew Obenshain, chief executive officer, bluebird bio. "It is an honor to be joining bluebird bi

      5/29/24 7:00:00 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Engine Capital Sends Letter to 2seventy's Board of Directors Outlining Steps to Maximize Shareholder Value

      Believes 2seventy Could Be Conservatively Worth ~$9 Per Share if the Company Exclusively Focuses on Its Most-Valuable Asset Abecma, Reduces Corporate Overhead and Makes Improvements to the Composition of the Management Team and Board Engine Capital LP, which owns approximately 3% of 2seventy bio, Inc.'s (NASDAQ:TSVT) ("2seventy" or the "Company") outstanding shares, today announced that it sent the below letter the Company's Board of Directors (the "Board"). *** December 6, 2023 2seventy bio, Inc. 60 Binney Street Cambridge, MA 02142 Attention: Board of Directors Dear Members of the Board: Engine Capital LP (together with its affiliates, "Engine" or "we"), is a meaningful shareh

      12/6/23 8:00:00 AM ET
      $BLUE
      $TSVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $BLUE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

      For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

      12/8/23 11:12:21 AM ET
      $BLUE
      $VRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • August 17, 2022 - FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood Transfusions

      For Immediate Release: August 17, 2022 Today, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.  “Today’s approval is an important advance in the treatment of beta-thalassemia, particularly in individuals who require ongoing

      8/17/22 2:12:27 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BLUE
    Financials

    Live finance-specific insights

    See more
    • bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

      - 74 patient starts completed or scheduled to date in 2024 across bluebird's commercial portfolio - - Third quarter 2024 net revenue of $10.6 million reflects quarter-to-quarter fluctuations in drug product infusions; anticipate at least $25 million of net revenue in the fourth quarter - - Management to host conference call today, November 14, 2024 at 8:00 am ET - bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird bio" or the "Company") today reported third quarter results and business highlights for the quarter ended September 30, 2024, including recent commercial and operational progress. "Patient starts more than doubled from our second to third quarter update, providing clear evidence

      11/14/24 7:00:00 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call

      bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird bio" or the "Company") today announced that it partially adjourned its annual meeting of stockholders ("Annual Meeting") on Wednesday, November 6, 2024, to allow the Company to solicit additional votes to obtain approval of Proposal 4, a reverse stock split, as described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on September 26, 2024 (the "proxy statement"). The Company's stockholders approved Proposals 1, 2, 5, 6 and 7, and did not approve Proposal 3 during the Annual Meeting held earlier today (all proposals as described in the proxy statement). The Annual Meeting will reconvene on December 4,

      11/6/24 4:15:00 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025

      Actions intended to reduce cash operating expenses by approximately 20% Management team to host conference call today, September 24 at 8:00 am ET Following a comprehensive review of its operations, bluebird bio, Inc. (NASDAQ:BLUE) today announced that the Company is implementing a restructuring intended to optimize the Company's cost structure and enable quarterly cash flow break-even in the second half of 2025. The restructuring is expected to result in a 20% reduction in cash operating expenses when fully realized in Q3 2025, compared to the prior reporting period. The initiative includes a reduction in the Company's workforce of approximately 25%. The Company's cash flow break-even tar

      9/24/24 7:00:00 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BLUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by bluebird bio Inc.

      SC 13G/A - bluebird bio, Inc. (0001293971) (Subject)

      11/14/24 4:39:36 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by bluebird bio Inc.

      SC 13G/A - bluebird bio, Inc. (0001293971) (Subject)

      11/14/24 4:27:32 PM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by bluebird bio Inc.

      SC 13G/A - bluebird bio, Inc. (0001293971) (Subject)

      11/14/24 10:32:08 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BLUE
    SEC Filings

    See more
    • Amendment: SEC Form SC 14D9/A filed by bluebird bio Inc.

      SC 14D9/A - bluebird bio, Inc. (0001293971) (Subject)

      5/9/25 8:44:57 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 14D9/A filed by bluebird bio Inc.

      SC 14D9/A - bluebird bio, Inc. (0001293971) (Subject)

      5/6/25 7:47:43 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC TO-T/A filed by bluebird bio Inc.

      SC TO-T/A - bluebird bio, Inc. (0001293971) (Subject)

      5/6/25 7:33:39 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BLUE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bluebirdbio upgraded by Analyst

      Analyst upgraded Bluebirdbio from Underweight to Neutral

      2/24/25 7:05:14 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Analyst initiated coverage on Bluebirdbio with a new price target

      Analyst initiated coverage of Bluebirdbio with a rating of Overweight and set a new price target of $29.00

      2/24/25 7:04:33 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Bluebirdbio downgraded by Analyst

      Analyst downgraded Bluebirdbio from Neutral to Underweight

      11/18/24 4:13:05 AM ET
      $BLUE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care